Jamp Bilastine Oral Solution 2.5 mg 0-Unassigned ; Solution is a Health Canada–registered human drug (DIN 02448262) held by Jamp Pharma Corporation, containing Bilastine. Health Canada lists its status as Marketed (status date 21 Apr 2026). Nexara Health has matched 206 registrations of Bilastine across 25 other regulated markets.
Health Canada registration
| DIN | 02448262 |
|---|---|
| Brand name | Jamp Bilastine Oral Solution |
| Active ingredient | Bilastine |
| Strength | 2.5 mg |
| Dosage form | 0-Unassigned ; Solution |
| Route | 0-Unassigned ; Oral |
| Company | Jamp Pharma Corporation |
| Status | Marketed — 21 Apr 2026 |
| Class | Human |
| ATC | |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Status and company history
Changes Health Canada has recorded for this DIN, as observed by Nexara Health's weekly DPD comparison.
| Date | Field | From | To |
|---|---|---|---|
| 2026-09-03 | Status | Approved | Marketed |
| 2026-09-03 | Status | Approved | Marketed |
Bilastine registered in other markets
206 registrations of the same molecule in 25 national registries outside Canada (first 120 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Bahrain | Actine 20 | Msn Laboratories Private Limited, India. | 20 MG | Tablet | POM | NHRA |
| Bahrain | Bilaxten | Jazeera Pharmaceuticals Industries, Ksa. | 10 MG | Orodispersible Tablet | POM | NHRA |
| Bahrain | Bilaxten | Jazeera Pharmaceuticals Industries, Ksa. | 20 MG | Tablet | POM | NHRA |
| Bahrain | Bilaxten | Jazeera Pharmaceuticals Industries, Ksa. | 2.5 MG/ML | Oral Solution | POM | NHRA |
| Bahrain | Bilazap | Glenmark Pharmaceuticals Limited (Mumbai), India. | 20 MG | Tablet | POM | NHRA |
| Bulgaria | Arelasine | MSN Labs Europe Limited | 20 mg | таблетки | По лекарско предписание | BDA |
| Bulgaria | Biastine Polpharma | Zaklady Farmaceutyczne POLPHARMA S.A. | Allertec Effect 20 mg tablets | таблетки | По лекарско предписание | BDA |
| Bulgaria | Fortecal | Menarini International Operations Luxembourg S.A. | 20 mg orodispersible tablets | таблетки, диспергиращи се в устата | Без лекарско предписание | BDA |
| Bulgaria | Fortecal | Menarini International Operations Luxembourg S.A. | 20 mg tablets | таблетки | Без лекарско предписание | BDA |
| Bulgaria | Fortecal for children | Menarini International Operations Luxembourg S.A. | 10 mg orodispersible tablets | таблетки, диспергиращи се в устата | По лекарско предписание | BDA |
| Czech Republic | Abisax | — | 20MG | Tbl Nob | R | SUKL DLP |
| Czech Republic | Bilastin Teva | — | 20MG | Tbl Nob | R | SUKL DLP |
| Czech Republic | Bilastine Glenmark | — | 20MG | Tbl Nob | R | SUKL DLP |
| Czech Republic | Bilastine Medreg | — | 20MG | Tbl Nob | R | SUKL DLP |
| Czech Republic | Bilastine Polpharma | Zaklady Farmaceutyczne Polpharma SA, Starogard Gda�ski | 20MG | Tbl Nob | B | SUKL DLP |
| Czech Republic | Nestibil | — | 20MG | Tbl Nob | R | SUKL DLP |
| Czech Republic | Xados | — | 20MG | Tbl Nob | R | SUKL DLP |
| Czech Republic | Xados | — | 20MG | Por Tbl Dis | R | SUKL DLP |
| Denmark | Bilaska | Orifarm A/S | 20 mg | tabletter | Par-Imp | Laegemiddelstyrelsen |
| Denmark | Bilastin "2care4" | 2care4 ApS | 20 mg | tabletter | Par-Imp | Laegemiddelstyrelsen |
| Denmark | Bilastin "Nordic Prime" | Nordic Prime ApS | 20 mg | tabletter | Par-Imp | Laegemiddelstyrelsen |
| Denmark | Bilastin "Paranova" | Paranova Danmark ApS | 20 mg | tabletter | Par-Imp | Laegemiddelstyrelsen |
| Denmark | Revitelle | Menarini International Operation Luxembourg S.A. | 10 mg | smeltetabletter | Decentral procedure | Laegemiddelstyrelsen |
| Denmark | Revitelle | Menarini International Operation Luxembourg S.A. | 20 mg | tabletter | Decentral procedure | Laegemiddelstyrelsen |
| Denmark | Revitelle | Menarini International Operation Luxembourg S.A. | 2,5 mg/ml | oral opløsning | Decentral procedure | Laegemiddelstyrelsen |
| Finland | Revitelle | Menarini International Operations Luxembourg S.A. | 10 mg | tabletti, suussa hajoava | Myyntilupa myönnetty | Fimea Perusrekisteri |
| Finland | Revitelle | Menarini International Operations Luxembourg S.A. | 2.5 mg/ml | oraaliliuos | Myyntilupa myönnetty | Fimea Perusrekisteri |
| Finland | Revitelle | Menarini International Operations Luxembourg S.A. | 20 mg | tabletti, suussa hajoava | Myyntilupa myönnetty | Fimea Perusrekisteri |
| Finland | Revitelle | Menarini International Operations Luxembourg S.A. | 20 mg | tabletti | Myyntilupa myönnetty | Fimea Perusrekisteri |
| Greece | BILARGEN OR.DISP.TA 10MG/TAB BTx10 or.disp.tab (1 blister x10) OPA/AL/PVC/AL blister σε χάρτινο κουτί | Menarini Inter.operat.luxemburg SA, Luxemburg | reimbursed | MoH deltio timwn | ||
| Greece | BILARGEN OR.DISP.TA 10MG/TAB BTx20 or.disp.tab (2 blister x10) OPA/AL/PVC/AL blister σε χάρτινο κουτί | Menarini Inter.operat.luxemburg SA, Luxemburg | reimbursed | MoH deltio timwn | ||
| Greece | BILARGEN ORAL.SOL 2.5MG/ML BTx1 bottle x120 ML Bottle amber glass, Type III (με δοσιμετρικό κυπελάκι) | Menarini Inter.operat.luxemburg SA, Luxemburg | reimbursed | MoH deltio timwn | ||
| Greece | BILARGEN TABLET 20MG/TAB BTx30 TABS (σε BLISTER) (σε BLISTER) | Menarini Inter.operat.luxemburg SA, Luxemburg | reimbursed | MoH deltio timwn | ||
| Greece | Bilargen® Ey.dro.sol 6mg/mL Bt X 1 Multi-Dose Ldpe X 5 mL Περιεκτης Πολλαπλων Δοσεων Αποτελουμενο Απο Φιαλη Lpde Με Hpde Ρυγχος Και Βιδωτο Πωμα | Menarini Inter.operat.luxemburg SA, Luxemburg | reimbursed | MoH deltio timwn | ||
| Greece | Bilargen® Or.disp.ta 20mg/Tab Btx20x1 Σε Opa/Alu/Pvc//Alu Διατρητες Κυψελες Μοναδας Δοσης (Perforated Unit Dose Blisters) | Menarini Inter.operat.luxemburg SA, Luxemburg | reimbursed | MoH deltio timwn | ||
| Greece | Bilaz® Ey.dro.sol 6mg/mL Bt X 1 Multi-Dose Ldpe X 5 mL Περιεκτης Πολλαπλων Δοσεων Αποτελουμενο Απο Φιαλη Lpde Με Hpde Ρυγχος Και Βιδωτο Πωμα | Menarini Inter.operat.luxemburg SA, Luxemburg | reimbursed | MoH deltio timwn | ||
| Greece | BILAZ® OR.DISP.TA 10MG/TAB BTx10 or.disp.tab (1 blister x10) OPA/AL/PVC/AL blister σε χάρτινο κουτί | Menarini Inter.operat.luxemburg SA, Luxemburg | reimbursed | MoH deltio timwn | ||
| Hong Kong | Bilastine Tablets 20mg | Controlled Medications Limited | Registered | DH Drug Office | ||
| Hong Kong | Bilazin 20 Tablets 20mg | Hong Kong Medical Supplies Ltd | Registered | DH Drug Office | ||
| Hong Kong | Labixten Oral Solution 2.5mg/mL | A. Menarini Hong Kong Limited | Registered | DH Drug Office | ||
| Hong Kong | Labixten Orodispersible Tablets 10mg | A. Menarini Hong Kong Limited | Registered | DH Drug Office | ||
| Hong Kong | Labixten Tablets 20mg | A. Menarini Hong Kong Limited | Registered | DH Drug Office | ||
| Hong Kong | Vilarin Tablets 20mg | Vickmans Laboratories Ltd | Registered | DH Drug Office | ||
| Ireland | Bilhista 20 mg tablets | Alfred E Tiefenbacher (GmbH & Co. KG) | Tablet | Not marketed | HPRA | |
| Ireland | Drynol 10 mg orodispersible tablet | Menarini International Operations Luxembourg S.A. | Orodispersible tablet | Marketed | HPRA | |
| Ireland | Drynol 2.5 mg/ml oral solution | Menarini International Operations Luxembourg S.A. | Oral solution | Marketed | HPRA | |
| Ireland | Drynol 20 mg orodispersible tablets | Menarini International Operations Luxembourg S.A. | Orodispersible tablet | Not marketed | HPRA | |
| Ireland | Drynol 20 mg Tablets | Menarini International Operations Luxembourg S.A. | Tablet | Marketed | HPRA | |
| Ireland | Drynol 20 mg Tablets | IMED Healthcare Ltd., | Tablet | Unknown | HPRA | |
| Ireland | Drynol 6 mg/mL eye drops, solution | Menarini International Operations Luxembourg S.A. | Eye drops, solution | Not marketed | HPRA | |
| Jordan | Bilaxten 10mg Oral dispersible tablets | Hikma Pharmaceuticals.ind/Jordan | 10 MG | Oral dispersible tablet | NEW APPLICATION | JFDA drug registrations |
| Jordan | Bilaxten 2.5mg Oral solution | The Arab Pharmaceutical Manufacturing PSC/Salt | 2.5 MG | Oral solution | NEW APPLICATION | JFDA drug registrations |
| Luxembourg | Bilastine EG CPR. 20 mg 1*100 cpr.ss blist. | — | R | CNS liste positive | ||
| Luxembourg | Bilastine EG CPR. 20 mg 1*50 cpr.ss blist. | — | R | CNS liste positive | ||
| Luxembourg | Bilastine Eurogenerics CPR. 20 mg 1*100 comprimés | — | R | CNS liste positive | ||
| Luxembourg | Bilastine Eurogenerics CPR. 20 mg 1*30 comprimés | — | R | CNS liste positive | ||
| Malaysia | Beltas 20mg Tablets | Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. | Prescription | PRODUCT APPROVED | NPRA | |
| Malaysia | Biladrive-20 Bilastine Orally Disintegrating Tablet 20 mg | Mega Lifesciences Sdn. Bhd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malaysia | Bilaxten 10mg Orodispersible Tablets | A. Menarini Singapore Pte. Ltd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malaysia | Bilaxten 2.5 mg/ml Oral Solution | A. Menarini Singapore Pte. Ltd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malaysia | Bilaxten 20mg Orodispersible Tablets | A. Menarini Singapore Pte. Ltd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malaysia | BILAXTEN 20mg Tablets | A. Menarini Singapore Pte. Ltd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malaysia | Bilazine 20mg Tablets | Medispec (M) Sdn. Bhd. | Prescription | PRODUCT APPROVED | NPRA | |
| Malaysia | Bliztin 20 mg Tablet | Spg Pharma (Malaysia) Sdn Bhd | Prescription | PRODUCT APPROVED | NPRA | |
| Malta | Elozar 20 mg tablets | Delorbis Pharmaceuticals Limited | Tablet | Authorised | Medicines Authority | |
| Malta | Gosall 10mg orodispersible tablets | Menarini International Operations Luxembourg S.A | Orodispersible Tablet | Authorised | Medicines Authority | |
| Malta | Gosall 20 mg orodispersible tablets | Menarini International Operations Luxembourg S.A | Orodispersible Tablet | Authorised | Medicines Authority | |
| Malta | Gosall 20mg tablets | Menarini International Operations Luxembourg S.A | Tablet | Authorised | Medicines Authority | |
| Malta | Gosall 20mg Tablets | Menarini International Operations Luxembourg S.A | Tablet | Authorised | Medicines Authority | |
| Norway | Zilas tab 20 mg | Menarini International O.L. SA | 10 | Tablett | Aktiv oppføring | FEST (DMP) |
| Poland | Adablix | Adamed Pharma S.A. | 10 mg | Tabletki ulegające rozpadowi w jamie ustnej | 2028-04-21 | URPL RPL |
| Poland | Adablix | Adamed Pharma S.A. | 20 mg | Tabletki | Bezterminowe | URPL RPL |
| Poland | Allertec Effect | Zakłady Farmaceutyczne POLPHARMA S.A. | 20 mg | Tabletki | 2027-08-03 | URPL RPL |
| Poland | Bellix | Aurovitas Pharma Polska Sp. z o.o. | 20 mg | Tabletki | 2027-10-04 | URPL RPL |
| Poland | Bellix Allergy | Aurovitas Pharma Polska Sp. z o.o. | 20 mg | Tabletki | 2030-01-13 | URPL RPL |
| Poland | Bilabella | Aristo Pharma Sp. z o.o. | 20 mg | Tabletki | Bezterminowe | URPL RPL |
| Poland | Bilagra | InPharm Sp. z o.o. | 20 mg | Tabletki | 2030-11-25 | URPL RPL |
| Poland | Bilagra | Teva B.V. | 20 mg | Tabletki | Bezterminowe | URPL RPL |
| Romania | ARELASINE 20 mg | — | 20mg | Compr. | PRF | ANMDMR nomenclator |
| Romania | ARELASINE 20 mg | — | 20mg | Compr. | PRF | ANMDMR nomenclator |
| Romania | ARELASINE 20 mg | — | 20mg | Compr. | PRF | ANMDMR nomenclator |
| Romania | ARELASINE 20 mg | — | 20mg | Compr. | PRF | ANMDMR nomenclator |
| Romania | ARELASINE 20 mg | — | 20mg | Compr. | PRF | ANMDMR nomenclator |
| Romania | BILASTINA GEMAX PHARMA 20 mg | — | 20mg | Compr. | PRF | ANMDMR nomenclator |
| Romania | BILASTINA GEMAX PHARMA 20 mg | — | 20mg | Compr. | PRF | ANMDMR nomenclator |
| Romania | BILASTINA GEMAX PHARMA 20 mg | — | 20mg | Compr. | PRF | ANMDMR nomenclator |
| Saudi Arabia | Bilaxten | — | 10 | Inactive | SFDA | |
| Saudi Arabia | Bilaxten | — | 2.5 | Inactive | SFDA | |
| Saudi Arabia | Bilaxten 20mg Tablet | — | 20 | Inactive | SFDA | |
| Saudi Arabia | Bilazap | — | 20 | Inactive | SFDA | |
| Serbia | Actine | Pharmas D.o.o. Beograd | REGISTRACIJA | ALIMS | ||
| Serbia | Actine | Pharmas D.o.o. Beograd | REGISTRACIJA | ALIMS | ||
| Serbia | Alergofen® | Hemofarm Ad Vršac | REGISTRACIJA | ALIMS | ||
| Serbia | Aprixa | Zentiva Pharma D.o.o. | REGISTRACIJA | ALIMS | ||
| Serbia | Aprixa | Zentiva Pharma D.o.o. | REGISTRACIJA | ALIMS | ||
| Serbia | Nixar® | Berlin-Chemie A. Menarini Distribution D.o.o. | OBNOVA | ALIMS | ||
| Serbia | Nixar® | Berlin-Chemie A. Menarini Distribution D.o.o. | REGISTRACIJA | ALIMS | ||
| Serbia | Nixar® | Berlin-Chemie A. Menarini Distribution D.o.o. | REGISTRACIJA | ALIMS | ||
| Singapore | Aligrin Tablet 20mg | A. Menarini Singapore Pte. Ltd. | 20MG | Tablet | Prescription Only | HSA |
| Singapore | Bilaxten Oral Solution 2.5mg/mL | A. Menarini Singapore Pte. Ltd. | 2.5MG/ML | Solution | Prescription Only | HSA |
| Singapore | Bilaxten Orodispersible Tablet 10mg | A. Menarini Singapore Pte. Ltd. | 10MG/TABLET | Tablet, Orally Disintegrating | Prescription Only | HSA |
| Singapore | Bilaxten Orodispersible Tablet 20 mg | A. Menarini Singapore Pte. Ltd. | 20 MG | Tablet, Orally Disintegrating | Prescription Only | HSA |
| Singapore | BILAXTEN TABLET 20 mg | A. Menarini Singapore Pte. Ltd. | 20.00 mg | Tablet | Prescription Only | HSA |
| Singapore | Bilaxten Tablet 20 mg (Pharmacy Only) | A. Menarini Singapore Pte. Ltd. | 20.00 mg | Tablet | Pharmacy Only | HSA |
| Singapore | Bylastin Tablet 20mg | Miraco Nutripharm Pte. Ltd. | 20.0mg | Tablet | Prescription Only | HSA |
| Singapore | Elhist 20 Tablets 20mg | United Italian Trading Corporation (Private) Limited | 20 mg | Tablet | Pharmacy Only | HSA |
| Slovakia | Abisax 20 mg | Glm-Cz | tbl 50x20 mg (blis.Al/Al) | 3G | MZ SR kategorizacia | |
| Slovakia | Abisax 20 mg | Glm-Cz | tbl 30x20 mg (blis.Al/Al) | 3G | MZ SR kategorizacia | |
| Slovakia | Nestibil | Znt-3 | tbl 30x20 mg (blis.Al/Al) | G | MZ SR kategorizacia | |
| Slovakia | Nestibil | Znt-3 | tbl 50x20 mg (blis.Al/Al) | 1G | MZ SR kategorizacia | |
| Slovakia | Omarit | Mnr | tbl 50x20 mg (blis.PA/Al/PVC/Al) | O | MZ SR kategorizacia | |
| Slovakia | Omarit | Mnr | tbl 30x20 mg (blis.PA/Al/PVC/Al) | O | MZ SR kategorizacia | |
| Slovakia | Omarit 10 mg orodispergovateľné tablety | Mnr | tbl oro 30x10 mg (blis.OPA/Al/PVC/Al) | O | MZ SR kategorizacia | |
| South Africa | Basmedene 20 | Trinity Pharma (Pty) Ltd | 20 mg | Tab | S2 | DoH SEP database |
| South Africa | Ilaxten | Menarini South Africa (Pty) Ltd | 20 mg | Tab | S2 | DoH SEP database |
| Taiwan | Bilastine | Lee Pharma Limited | （粉） | Registered | TFDA | |
| Taiwan | Bilastine | Lianyungang Guike Pharmaceutical CO., Ltd. | （粉） | Registered | TFDA | |
| Taiwan | Bilastine | Symed Labs Limited | （粉） | Registered | TFDA | |
| Taiwan | Bistin Tablets 20 mg | 生達化學製藥股份有限公司二廠 | 錠劑 | Registered | TFDA | |
| Taiwan | Labixten orodispersible tablets 10mg | A. Menarini Manufacturing Logistics And Services S.r.l (L’aquila Plant) | 口溶錠 | Registered | TFDA |
See every manufacturer of Bilastine worldwide →
Regulator price references for Bilastine
Published list or reimbursement prices for Bilastine presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.
| Country | Product | Strength | Pack | Price | Type | Source | As of |
|---|---|---|---|---|---|---|---|
| Bahrain | Bilaxten | 10mg | 30 | 2.63 BHD | retail (max) | NHRA | 2026-09-01 |
| Bahrain | Bilaxten | 2.5mg/1ml | 120ML | 2.63 BHD | retail (max) | NHRA | 2026-09-01 |
| Bahrain | Bilaxten | 20mg | 20 | 2.93 BHD | retail (max) | NHRA | 2026-09-01 |
| Bahrain | Bilazap | 20mg | 20 | 4.15 BHD | retail (max) | NHRA | 2026-09-01 |
| Bahrain | Actine 20 | 20mg | 30 | 4.17 BHD | retail (max) | NHRA | 2026-09-01 |
| Greece | BILARGEN OR.DISP.TA 10MG/TAB BTx10 or.disp.tab (1 blister x10) OPA/AL/PVC/AL blister σε χάρτινο κουτί | 10mg | 2.47 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | BILAZ® OR.DISP.TA 10MG/TAB BTx10 or.disp.tab (1 blister x10) OPA/AL/PVC/AL blister σε χάρτινο κουτί | 10mg | 2.47 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | BILAZ® OR.DISP.TA 10MG/TAB BTx20 or.disp.tab (2 blister x10) OPA/AL/PVC/AL blister σε χάρτινο κουτί | 10mg | 3.92 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | BILARGEN OR.DISP.TA 10MG/TAB BTx20 or.disp.tab (2 blister x10) OPA/AL/PVC/AL blister σε χάρτινο κουτί | 10mg | 3.92 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | BILARGEN TABLET 20MG/TAB BTx30 TABS (σε BLISTER) (σε BLISTER) | 20mg | 4.44 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | BILAZ® TABLET 20MG/TAB BTx30 TABS (σε BLISTER) (σε BLISTER) | 20mg | 4.44 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | Bilargen® Or.disp.ta 20mg/Tab Btx20x1 Σε Opa/Alu/Pvc//Alu Διατρητες Κυψελες Μοναδας Δοσης (Perforated Unit Dose Blisters) | 20mg | 4.57 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | Bilaz® Or.disp.ta 20mg/Tab Bt X 20 X 1 Σε Opa/Alu/Pvc//Alu Διατρητες Κυψελες Μοναδας Δοσης (Perforated Unit Dose Blisters) | 20mg | 4.57 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | BILARGEN ORAL.SOL 2.5MG/ML BTx1 bottle x120 ML Bottle amber glass, Type III (με δοσιμετρικό κυπελάκι) | 2.5mg/1ml | 5.33 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | BILAZ® ORAL.SOL 2.5MG/ML BTx1 bottle x120 ML Bottle amber glass, Type III (με δοσιμετρικό κυπελάκι) | 2.5mg/1ml | 5.33 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | Bilargen® Ey.dro.sol 6mg/mL Bt X 1 Multi-Dose Ldpe X 5 mL Περιεκτης Πολλαπλων Δοσεων Αποτελουμενο Απο Φιαλη Lpde Με Hpde Ρυγχος Και Βιδωτο Πωμα | 6mg/1ml | 10.25 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | Bilaz® Ey.dro.sol 6mg/mL Bt X 1 Multi-Dose Ldpe X 5 mL Περιεκτης Πολλαπλων Δοσεων Αποτελουμενο Απο Φιαλη Lpde Με Hpde Ρυγχος Και Βιδωτο Πωμα | 6mg/1ml | 10.25 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Luxembourg | Bilastine Eurogenerics CPR. 20 mg 1*30 comprimés | 20mg | 7.79 EUR | reimbursement | CNS liste positive | 2026-09-05 | |
| Luxembourg | Bilastine EG CPR. 20 mg 1*50 cpr.ss blist. | 20mg | 9.63 EUR | reimbursement | CNS liste positive | 2026-09-05 | |
| Luxembourg | Bilastine EG CPR. 20 mg 1*100 cpr.ss blist. | 20mg | 13.77 EUR | reimbursement | CNS liste positive | 2026-09-05 | |
| Luxembourg | Bilastine Eurogenerics CPR. 20 mg 1*100 comprimés | 20mg | 14.68 EUR | reimbursement | CNS liste positive | 2026-09-05 | |
| Norway | Zilas | 20mg | 10 stk | 57.60 NOK | max AUP (pharmacy retail) | DMP (Statens legemiddelverk) maksimalpris | 2026-09-07 |
| Saudi Arabia | Bilazap | 20.80 SAR | public | SFDA | 2026-09-01 | ||
| Saudi Arabia | Bilaxten 20mg Tablet | 20mg | 22.30 SAR | public | SFDA | 2026-09-01 | |
| Saudi Arabia | Bilaxten | 26.75 SAR | public | SFDA | 2026-09-01 | ||
| Saudi Arabia | Bilaxten | 26.75 SAR | public | SFDA | 2026-09-01 | ||
| Slovakia | Abisax 20 mg | 20mg | tbl 30x20 mg (blis.Al/Al) | 4.22 EUR | categorised final price | MZ SR kategorizacia | 2026-09-02 |
| Slovakia | Omarit | 20mg | tbl 30x20 mg (blis.PA/Al/PVC/Al) | 4.94 EUR | categorised final price | MZ SR kategorizacia | 2026-09-02 |
| Slovakia | Nestibil | 20mg | tbl 30x20 mg (blis.Al/Al) | 7.17 EUR | categorised final price | MZ SR kategorizacia | 2026-09-02 |
| Slovakia | Abisax 20 mg | 20mg | tbl 50x20 mg (blis.Al/Al) | 7.86 EUR | categorised final price | MZ SR kategorizacia | 2026-09-02 |
| Slovakia | Nestibil | 20mg | tbl 50x20 mg (blis.Al/Al) | 7.86 EUR | categorised final price | MZ SR kategorizacia | 2026-09-02 |
| Slovakia | Omarit 10 mg orodispergovateľné tablety | 10mg | tbl oro 30x10 mg (blis.OPA/Al/PVC/Al) | 8.57 EUR | categorised final price | MZ SR kategorizacia | 2026-09-02 |
| Slovakia | Omarit | 20mg | tbl 50x20 mg (blis.PA/Al/PVC/Al) | 13.03 EUR | categorised final price | MZ SR kategorizacia | 2026-09-02 |
| South Africa | Basmedene 20 | 20mg | 20 | 192.37 ZAR | single exit price | DoH SEP database | 2026-09-01 |
| South Africa | Ilaxten | 20mg | 20 | 240.46 ZAR | single exit price | DoH SEP database | 2026-09-01 |
| United Arab Emirates | Bilaxten® 2.5 mg/ml | 2.5mg/1ml | 120 ml Amber Glass Bottle | 27.00 AED | public | EDE | 2026-08-31 |
| United Arab Emirates | Bilaxten® 10 mg | 10mg | 30's (10's Blister x 3) | 27.00 AED | public | EDE | 2026-08-31 |
| United Arab Emirates | BILAXTEN® 20 mg | 20mg | 20's (10's Blister x 2) | 32.00 AED | public | EDE | 2026-08-31 |
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Jamp Bilastine Oral Solution (DIN 02448262) marketed in Canada?
Yes. Health Canada lists DIN 02448262 as Marketed as of 21 Apr 2026.
Who holds the Canadian licence for this product?
Jamp Pharma Corporation is the company of record in the Health Canada Drug Product Database.
Is Bilastine registered outside Canada?
Yes — Nexara Health has matched 206 registrations in 25 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02448262, status date 2026-04-21; national medicine registries: ALIMS, ANMDMR nomenclator, BDA, CNS liste positive, DH Drug Office, DoH SEP database, FEST (DMP), Fimea Perusrekisteri, HPRA, HSA, JFDA drug registrations, Laegemiddelstyrelsen, Medicines Authority, MoH deltio timwn, MZ SR kategorizacia, NHRA, NPRA, SFDA, SUKL DLP, TFDA, URPL RPL; price sources: CNS liste positive, DMP (Statens legemiddelverk) maksimalpris, DoH SEP database, EDE, MoH deltio timwn, MZ SR kategorizacia, NHRA, SFDA. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02448262, status date 2026-04-21; national medicine registries: ALIMS, ANMDMR nomenclator, BDA, CNS liste positive, DH Drug Office, DoH SEP database, FEST (DMP), Fimea Perusrekisteri, HPRA, HSA, JFDA drug registrations, Laegemiddelstyrelsen, Medicines Authority, MoH deltio timwn, MZ SR kategorizacia, NHRA, NPRA, SFDA, SUKL DLP, TFDA, URPL RPL; price sources: CNS liste positive, DMP (Statens legemiddelverk) maksimalpris, DoH SEP database, EDE, MoH deltio timwn, MZ SR kategorizacia, NHRA, SFDA.
Health Canada Drug Product Database (DPD), DIN 02448262, status date 2026-04-21; national medicine registries: ALIMS, ANMDMR nomenclator, BDA, CNS liste positive, DH Drug Office, DoH SEP database, FEST (DMP), Fimea Perusrekisteri, HPRA, HSA, JFDA drug registrations, Laegemiddelstyrelsen, Medicines Authority, MoH deltio timwn, MZ SR kategorizacia, NHRA, NPRA, SFDA, SUKL DLP, TFDA, URPL RPL; price sources: CNS liste positive, DMP (Statens legemiddelverk) maksimalpris, DoH SEP database, EDE, MoH deltio timwn, MZ SR kategorizacia, NHRA, SFDA. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.